| Literature DB >> 10508710 |
Abstract
The major barrier to clinically successful pig-to-human xenotransplantation is antibody- and complement-dependent hyperacute rejection, known to be due to host anti-Galalpha(1,3)Gal antibodies. Strategies aimed at eliminating hyperacute rejection involve transgenic approaches to eliminate or reduce expression of Galalpha(1,3)Gal or to reduce complement activation; some of these are now in clinical trials in primates. Another important role of Galalpha(1,3)Gal that is becoming more evident is in antibody-dependent and -independent xenograft rejection that is mediated by natural killer cells and monocytes.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10508710 DOI: 10.1016/s0952-7915(99)00011-4
Source DB: PubMed Journal: Curr Opin Immunol ISSN: 0952-7915 Impact factor: 7.486